Graeme Milligan for receiving the Order of British Empire from King Charles III in recognition of his Graeme Milligan was awarded the Order of British Empire by King Charles III for services to Biochemical

Bryan Roth, Sudarshan Rajagopal, and Graeme Milligan. Save the date! Dr.

Graeme Milligan and their colleagues research on Pro-phagocytic function and structural basis of GPR84 Biosciences' GPCR Assay Septerna: making another run on GPCRs Addex Mglu2 Nam Cognition Program Receives €4 Million

World Congress of Basic and Clinical Pharmacology GPCR Jobs HIGHLIGHT Research Associate - Professor Graeme Milligan HIGHLIGHT Postdoc in Molecular Pharmacology - The Hauser Group NEW Postdoctoral Scholar – iPSC

Classified GPCR News from September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million World Congress of Basic and Clinical Pharmacology GPCR Jobs HIGHLIGHT Research Associate - Professor Graeme Milligan HIGHLIGHT Postdoc in Molecular Pharmacology - The Hauser Group Senior Scientist/Staff Scientist

World Congress of Basic and Clinical Pharmacology GPCR Jobs HIGHLIGHT Research Associate - Professor Graeme Milligan NEW   Postdoc in Molecular Pharmacology - The Hauser Group NEW Senior Scientist/Staff Scientist

Sara Marsango and Graeme Milligan for their research on the Regulation of the pro-inflammatory G protein-coupled Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings Neurocrine Biosciences

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million for patients with central nervous system (CNS) disorders, today announced receipt of the first $15 million

December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Capital LLC, a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS, which is equivalent to CHF 1.00 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered warrants to purchase up to 9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded Warrants” and together with the Unregistered Warrants, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $6.50 per ADS, will become exercisable in 60 days after their date of issuance and will expire six years from their date of issuance. The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise." Read more at the source #DrGPCR #GPCR #IndustryNews

July 2022 " Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a healthcare-focused institutional investor, to sell 3,300,000 shares in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which is equivalent to CHF 0.27 per share. Each ADS represents six shares. Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement. The Unregistered Warrants have an exercise price of $1.90 per ADS, will become exercisable in 60 days after their date of issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR #IndustryNews

The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million , including an investment of $3 million from Virtus Inspire Venture Partners.

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators Therapeutics , founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million

well known that immune challenges, such as exposure to lipopolysaccharide, the main component of the Gram-negative

October 2022 "Neisseria meningitidis is a Gram-negative opportunistic pathogen that is responsible for

This study demonstrates the feasibility of producing milligram quantities of hTAS1R2-VFT to further characterize

constitutively interacts with β-arrestin2, and constitutively internalizes in a β-arrestin2-dependent manner (Gillilan